Juan Herrador
Overview
Explore the profile of Juan Herrador including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
139
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rodriguez-Leor O, Cid-Alvarez B, de Prado A, Rossello X, Serrador A, Lopez-Palop R, et al.
Rev Esp Cardiol
. 2020 Oct;
73(12):994-1002.
PMID: 33071427
Introduction And Objectives: The COVID-19 outbreak has had an unclear impact on the treatment and outcomes of patients with ST-segment elevation myocardial infarction (STEMI). The aim of this study was...
2.
Rodriguez-Leor O, Cid-Alvarez B, de Prado A, Rossello X, Serrador A, Lopez-Palop R, et al.
Rev Esp Cardiol (Engl Ed)
. 2020 Sep;
73(12):994-1002.
PMID: 32917566
Introduction And Objectives: The COVID-19 outbreak has had an unclear impact on the treatment and outcomes of patients with ST-segment elevation myocardial infarction (STEMI). The aim of this study was...
3.
Diaz Fernandez J, Sanchez Gonzalez C, Navarro M, Fernandez Guerrero J, Gomez Menchero A, Briales J, et al.
Tex Heart Inst J
. 2011 Aug;
38(4):386-91.
PMID: 21841866
Percutaneous coronary intervention with drug-eluting stents is an alternative for patients with high-risk unprotected left main coronary artery disease; those with diabetes mellitus are at even higher risk. Recent advances...
4.
Pan M, de Lezo J, Medina A, Romero M, Delgado A, Segura J, et al.
Am Heart J
. 2006 Dec;
153(1):15.e1-7.
PMID: 17174630
Background: Drug-eluting stents have been shown to reduce restenosis in many types of lesions. The purpose of this article is to assess the efficacy of sirolimus- and paclitaxel-eluting stents in...
5.
Arias M, Fernandez-Guerrero J, Herrador J, Pagola C
Am J Emerg Med
. 2006 Feb;
24(2):253-4.
PMID: 16490665
No abstract available.
6.
Pan M, de Lezo J, Medina A, Romero M, Delgado A, Segura J, et al.
Rev Esp Cardiol
. 2005 Dec;
58(11):1278-86.
PMID: 16324581
Introduction And Objectives: In vitro studies show that stents deform when dilated laterally to access a side branch. This phenomenon may be avoided by use of a kissing balloon at...
7.
Medina A, de Lezo J, Pan M, Delgado A, Segura J, Pavlovic D, et al.
Tex Heart Inst J
. 2005 May;
32(1):11-5.
PMID: 15902815
We analyzed the clinical, angiographic, and late intravascular ultrasonographic findings from 140 patients whose in-stent restenosis was treated with sirolimus-eluting stents. In-stent restenosis remains the main limitation to percutaneous coronary...
8.
Pan M, de Lezo J, Medina A, Romero M, Segura J, Pavlovic D, et al.
Am Heart J
. 2004 Nov;
148(5):857-64.
PMID: 15523318
Background: Rapamycin-eluting stents (RES) have been shown to reduce restenosis in many types of lesions. However, the ideal strategy for the treatment of coronary bifurcated lesions has not been established...
9.
de Lezo J, Medina A, Pan M, Delgado A, Segura J, Pavlovic D, et al.
Am Heart J
. 2004 Sep;
148(3):481-5.
PMID: 15389236
Background: Conventional bare stents have been used to treat unprotected left main (LM) coronary artery stenosis. However, restenosis remains the main limitation. Since rapamycin-eluting stents (RES) appear to inhibit neointimal...